相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。HDAC3 increases HMGB3 expression to facilitate the immune escape of breast cancer cells via down-regulating microRNA-130a-3p
Zonglin Chen et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2021)
被撤回的出版物: LINC00504 Promotes the Malignant Biological Behavior of Breast Cancer Cells by Upregulating HMGB3 via Decoying MicroRNA-876-3p (Retracted article. See vol. 15, pg. 739, 2023)
Hao Yu et al.
CANCER MANAGEMENT AND RESEARCH (2021)
Targeting Innate Immunity in Cancer Therapy
Srikrishnan Rameshbabu et al.
VACCINES (2021)
Next generation of immune checkpoint inhibitors and beyond
Julian A. Marin-Acevedo et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Immunotherapies targeting stimulatory pathways and beyond
Julian A. Marin-Acevedo et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Pancancer survival analysis of cancer hallmark genes
Adam Nagy et al.
SCIENTIFIC REPORTS (2021)
Demethylated miR-216a Regulates High Mobility Group Box 3 Promoting Growth of Esophageal Cancer Cells Through Wnt/β-Catenin Pathway
Cheng-Xi Sun et al.
FRONTIERS IN ONCOLOGY (2021)
Impact of Immunotherapy on CD4 T Cell Phenotypes and Function in Cancer
Margaux Saillard et al.
VACCINES (2021)
Microsatellite Instability in Colorectal Cancers: Carcinogenesis, Neo-Antigens, Immuno-Resistance and Emerging Therapies
Violaine Randrian et al.
CANCERS (2021)
HMGB1: an overview of its versatile roles in the pathogenesis of colorectal cancer
Kim Jun Cheng et al.
CELLULAR ONCOLOGY (2020)
Topoisomerase 1 cleavage complex enables pattern recognition and inflammation during senescence
Bo Zhao et al.
NATURE COMMUNICATIONS (2020)
Targeting Chromosomal Architectural HMGB Proteins Could Be the Next Frontier in Cancer Therapy
Anirban Mukherjee et al.
CANCER RESEARCH (2020)
TIMER2.0 for analysis of tumor-infiltrating immune cells
Taiwen Li et al.
NUCLEIC ACIDS RESEARCH (2020)
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
Yuanyuan Zhang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
Immunological Significance of HMGB1 Post-Translational Modification and Redox Biology
Man Sup Kwak et al.
FRONTIERS IN IMMUNOLOGY (2020)
High Mobility Group Box 1 in Human Cancer
Bernardo L. Rapoport et al.
CELLS (2020)
High mobility group box 1 (HMGB1): a pivotal regulator of hematopoietic malignancies
Shunling Yuan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
The HMGB1-2 Ovarian Cancer Interactome. The Role of HMGB Proteins and Their Interacting Partners MIEN1 and NOP53 in Ovary Cancer and Drug-Response
Maria Camara-Quilez et al.
CANCERS (2020)
Biological functions and theranostic potential of HMGB family members in human cancers
Liaoran Niu et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Targeting HMGB3/hTERT axis for radioresistance in cervical cancer
Zongjuan Li et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
Detection of immunogenic cell death and its relevance for cancer therapy
Jitka Fucikova et al.
CELL DEATH & DISEASE (2020)
TISIDB: an integrated repository portal for tumor-immune system interactions
Beibei Ru et al.
BIOINFORMATICS (2019)
Upregulation of PD-L1 via HMGB1-Activated IRF3 and NF-kB Contributes to UV Radiation-Induced Immune Suppression
Wei Wang et al.
CANCER RESEARCH (2019)
HMGB2 promotes the malignancy of human gastric cancer and indicates poor survival outcome
Guangfei Cui et al.
HUMAN PATHOLOGY (2019)
Targeting the High-Mobility Group Box 3 Protein Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin
Anirban Mukherjee et al.
CANCER RESEARCH (2019)
WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs
Yuxing Liao et al.
NUCLEIC ACIDS RESEARCH (2019)
HMGB3 silence inhibits breast cancer cell proliferation and tumor growth by interacting with hypoxia-inducible factor 1α
Jun Gu et al.
CANCER MANAGEMENT AND RESEARCH (2019)
Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients
Michael J. Duffy et al.
CLINICAL CHEMISTRY (2019)
HMGB1 modulates the balance between senescence and apoptosis in response to genotoxic stress
Je-Jung Lee et al.
FASEB JOURNAL (2019)
MicroRNA-329 upregulation impairs the HMGB2/β-catenin pathway and regulates cell biological behaviors in melanoma
You Mo et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Johnny on the Spot-Chronic Inflammation Is Driven by HMGB1
Carolina M. Gorgulho et al.
FRONTIERS IN IMMUNOLOGY (2019)
The Immune Landscape of Cancer (vol 48, pg 812, 2018)
Vesteinn Thorsson et al.
IMMUNITY (2019)
Interactions of high mobility group box protein 1 (HMGB1) with nucleic acids: Implications in DNA repair and immune responses
Pooja Mandke et al.
DNA REPAIR (2019)
LinkedOmics: analyzing multi-omics data within and across 32 cancer types
Suhas V. Vasaikar et al.
NUCLEIC ACIDS RESEARCH (2018)
HMGB2 is associated with malignancy and regulates Warburg effect by targeting LDHB and FBP1 in breast cancer
Deyuan Fu et al.
CELL COMMUNICATION AND SIGNALING (2018)
Next generation of immune checkpoint therapy in cancer: new developments and challenges
Julian A. Marin-Acevedo et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
Ming Yi et al.
MOLECULAR CANCER (2018)
High-mobility group box 1 protein orchestrates responses to tissue damage via inflammation, innate and adaptive immunity, and tissue repair
Marco E. Bianchi et al.
IMMUNOLOGICAL REVIEWS (2017)
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
Mizuki Nishino et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses
Zefang Tang et al.
NUCLEIC ACIDS RESEARCH (2017)
Expression levels and clinical significance of hepsin and HMGB1 proteins in cervical carcinoma
Hui Cheng et al.
ONCOLOGY LETTERS (2017)
UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses
Darshan S. Chandrashekar et al.
NEOPLASIA (2017)
Landscape of Microsatellite Instability Across 39 Cancer Types
Russell Bonneville et al.
JCO PRECISION ONCOLOGY (2017)
Clinical Value of High Mobility Group Box 1 and the Receptor for Advanced Glycation End-products in Head and Neck Cancer: A Systematic Review
Austin Nguyen et al.
INTERNATIONAL ARCHIVES OF OTORHINOLARYNGOLOGY (2016)
The Association of HMGB1 Expression with Clinicopathological Significance and Prognosis in Hepatocellular Carcinoma: A Meta-Analysis and Literature Review
Lu Zhang et al.
PLOS ONE (2014)
An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies
Domenica Musumeci et al.
PHARMACOLOGY & THERAPEUTICS (2014)
HMGB1 in Cancer: Good, Bad, or Both?
Rui Kang et al.
CLINICAL CANCER RESEARCH (2013)
SurvExpress: An Online Biomarker Validation Tool and Database for Cancer Gene Expression Data Using Survival Analysis
Raul Aguirre-Gamboa et al.
PLOS ONE (2013)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
HMGB1 conveys immunosuppressive characteristics on regulatory and conventional T cells
Clarissa Anni Wild et al.
INTERNATIONAL IMMUNOLOGY (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Overexpression of High-Mobility Group Box 2 Is Associated with Tumor Aggressiveness and Prognosis of Hepatocellular Carcinoma
Jung-Hee Kwon et al.
CLINICAL CANCER RESEARCH (2010)
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
Lionel Apetoh et al.
NATURE MEDICINE (2007)
Oncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles
Daniel R. Rhodes et al.
NEOPLASIA (2007)
分享论文
